Literature DB >> 30715622

MiR-449a-5p mediates mitochondrial dysfunction and phenotypic transition by targeting Myc in pulmonary arterial smooth muscle cells.

Chen Zhang1,2, Cui Ma2,3, Lixin Zhang2,3, Linlin Zhang4, Fengying Zhang4, Mingfei Ma4, Xiaodong Zheng5, Min Mao4, Tingting Shen6, Daling Zhu7,8,9,10.   

Abstract

MicroRNAs have been considered to participate in pulmonary arterial hypertension (PAH) and regulate numerous disease pathways in pulmonary vasculature. However, the molecular role in the pathologies has not yet been fully uncovered, particularly in the view of energy metabolism and vascular smooth muscle cell phenotypic regulation. Here, several altered miRNAs are founded in genome-wide miRNA sequencing analysis, in which miR-449a-5p was identified as a probable candidate in hypoxic PAH and verified such a decreasing trend. Moreover, we identify that miR-449a-5p plays critical role in both mitochondria metabolic dysfunction and phenotype transformation of pulmonary arterial smooth muscle cells. Subsequently, we initiate that the transcription factor Myc, which is negatively regulated by miR-449a-5p, results in the aberrant effects contributing to pulmonary arterial smooth muscle cell proliferation. Taken together, we demonstrated that the miR-449a-5p/Myc axis is indispensable for the development and progression of PAH. These results may serve as a significant implication for understanding and treatment of PAH. KEY MESSAGES: • The downregulation of miR-449a-5p occurs in both PAH-PAs and hypoxic PASMCs. • MiR-449a-5p is involved in hypoxia-induced mitochondria dysfunction of PASMCs. • MiR-449a-5p inhibits hypoxic phenotypic transition and proliferation of PASMCs. • The aberrant effects of MiR-449a-5p depend on downstream transcription factor Myc. • Myc contributes to mitochondria dysfunction and phenotype transformation in PAH.

Entities:  

Keywords:  Metabolism; MiR-449a-5p; Myc; Phenotypic transition; Pulmonary arterial hypertension

Mesh:

Substances:

Year:  2019        PMID: 30715622     DOI: 10.1007/s00109-019-01751-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  37 in total

1.  Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.

Authors:  Takuya Fukazawa; Yutaka Maeda; Junji Matsuoka; Tomoki Yamatsuji; Kaoru Shigemitsu; Ichiro Morita; Francesco Faiola; Mary L Durbin; Laura Soucek; Yoshio Naomoto
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 3.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

4.  Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice.

Authors:  Preeti Ahuja; Peng Zhao; Ekaterini Angelis; Hongmei Ruan; Paavo Korge; Aaron Olson; Yibin Wang; Eunsook S Jin; F Mark Jeffrey; Michael Portman; W Robb Maclellan
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 5.  The c-Myc target gene network.

Authors:  Chi V Dang; Kathryn A O'Donnell; Karen I Zeller; Tam Nguyen; Rebecca C Osthus; Feng Li
Journal:  Semin Cancer Biol       Date:  2006-07-25       Impact factor: 15.707

6.  Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis.

Authors:  Feng Li; Yunyue Wang; Karen I Zeller; James J Potter; Diane R Wonsey; Kathryn A O'Donnell; Jung-Whan Kim; Jason T Yustein; Linda A Lee; Chi V Dang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 7.  c-Myc: linking transformation and genomic instability.

Authors:  Edward V Prochownik
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

8.  Prognostic significance of "short-term" effects of chemotherapy on MYC and histone H3 mRNA levels in acute leukemia patients.

Authors:  D Venturelli; B Lange; F Narni; L Selleri; M T Mariano; U Torelli; A M Gewirtz; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 9.  Toward microRNA-based therapeutics for heart disease: the sense in antisense.

Authors:  Eva van Rooij; William S Marshall; Eric N Olson
Journal:  Circ Res       Date:  2008-10-24       Impact factor: 17.367

10.  Role for miR-204 in human pulmonary arterial hypertension.

Authors:  Audrey Courboulin; Roxane Paulin; Nellie J Giguère; Nehmé Saksouk; Tanya Perreault; Jolyane Meloche; Eric R Paquet; Sabrina Biardel; Steeve Provencher; Jacques Côté; Martin J Simard; Sébastien Bonnet
Journal:  J Exp Med       Date:  2011-02-14       Impact factor: 14.307

View more
  8 in total

1.  Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension.

Authors:  Jixing Wu; Qian Huang; Qinghai Li; Yiya Gu; Yuan Zhan; Ting Wang; Jinkun Chen; Zhilin Zeng; Yongman Lv; Jianping Zhao; Jie Xia; Jungang Xie
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

2.  miR-125a-5p inhibits glycolysis by targeting hexokinase-II to improve pulmonary arterial hypertension.

Authors:  Li Luo; Lusheng Xiao; Guili Lian; Huajun Wang; Liangdi Xie
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

Review 3.  An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension.

Authors:  Weifang Zhang; Zeying Tao; Fei Xu; Qian Diao; Juan Li; Lu Zhou; Yaxin Miao; Shanshan Xie; Jinjin Wan; Ruilai Xu
Journal:  Biomed Res Int       Date:  2021-10-07       Impact factor: 3.411

Review 4.  Non-Coding RNA Networks in Pulmonary Hypertension.

Authors:  Hongbin Zang; Qiongyu Zhang; Xiaodong Li
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

5.  Transcriptome Sequencing Reveals Key Genes in Three Early Phases of Osteogenic, Adipogenic, and Chondrogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Rats.

Authors:  Fanxiao Liu; Jun Dong; Peng Zhang; Dongsheng Zhou; Qingyu Zhang
Journal:  Front Mol Biosci       Date:  2022-02-11

6.  Mxi1-0 Promotes Hypoxic Pulmonary Hypertension Via ERK/c-Myc-dependent Proliferation of Arterial Smooth Muscle Cells.

Authors:  Liang Dong; Xinning Liu; Bo Wu; Chengwei Li; Xiaomin Wei; Gulinuer Wumaier; Xiujuan Zhang; Jing Wang; Jingwen Xia; Yuanyuan Zhang; Ruzetuoheti Yiminniyaze; Ning Zhu; Jing Li; Daibing Zhou; Youzhi Zhang; Shuanghui Li; Junzhu Lv; Shengqing Li
Journal:  Front Genet       Date:  2022-03-23       Impact factor: 4.599

Review 7.  MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction.

Authors:  Ji-Ru Zhang; Hai-Jian Sun
Journal:  Hypertens Res       Date:  2020-09-23       Impact factor: 3.872

Review 8.  MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension.

Authors:  Susana Carregal-Romero; Lucía Fadón; Edurne Berra; Jesús Ruíz-Cabello
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.